VK Paul says Bharat Biotech’s Bengaluru unit has fixed the glitches
VK Paul, Chairman, National COVID Task Force and Member-Health, NITI Aayog said Bharat Biotech, the maker of the Covaxin vaccine, has overcome the initial hiccups at its Bengaluru facility and is on track to proceed as planned.
Paul said the company has added two facilities at Ankleshwar and Bengaluru as part of its expansion plans. While Ankleshwar has started production, there were some difficulties in initial stabilization due to unforeseen circumstances as per schedule.
“Production was a bit behind expectations, but the issues have been addressed. The production it had planned will be achieved,” Paul said.
Bharat Biotech hopes to make 1 billion doses per year by the end of this year.
Business Standard has always worked hard to provide updated information and commentary on events that are of interest to you and have wider political and economic implications for the country and the world. Your encouragement and constant feedback on how to improve our offering has only strengthened our resolve and commitment to these ideals. Even during these difficult times arising out of COVID-19, we are committed to keeping you informed and updated with relevant news, authoritative views and sharp comments on relevant relevant issues. However, we have a request.
As we grapple with the economic impact of the pandemic, we need your support even more so that we can continue to provide you with more quality content. Our subscription model has received an encouraging response from many of you who have subscribed to our online content. Subscribing to more of our online content can only help us achieve our goals of providing you with better and more relevant content. We believe in independent, unbiased and credible journalism. Your support through more subscriptions can help us practice the journalism we’re committed to.
support quality journalism and Subscribe to Business Standard.